GC Genome Reports 7.44 Billion Won in Q1 Sales...Achieves First-Ever Quarterly Operating Profit
Sales Up 9.1%... Profitability Maintained for Four Consecutive Quarters
Balanced Growth in Obstetric, Cancer, and Rare Disease Testing
Core Product Sales Continue to Expand
GC Genome announced on May 15 that it recorded sales of 7.44 billion won and an operating profit of 140 million won in the first quarter of this year.
Compared to the same period last year, sales increased by 9.1%, and both operating profit and net profit returned to the black. The company explained that, thanks to growth in major testing segments, it achieved its first-ever quarterly operating profit surplus. This marks the fourth consecutive quarter of profitability since the second quarter of last year.
By business segment, steady growth was seen across the major testing portfolio, including obstetric tests, cancer diagnostics, and rare disease tests. The non-invasive prenatal test (G-NIPT) contributed to sales growth through increased demand driven by a rising birth rate and an expanding client base.
The multi-cancer early screening test "iCanSearch" also continued to grow. The company stated that higher awareness of its tests and an increase in clients have contributed to improved performance.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A representative from GC Genome said, "We achieved our first-ever quarterly operating profit surplus based on the stable growth of our main testing portfolio and a profit-focused management strategy," adding, "We will continue our growth momentum through core growth products and new services."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.